January 31, 2019
Merck Serono said on January 30 that it has filed an application in Japan for the anti-PD-L1 antibody Bavencio (avelumab) seeking the first-line use for treatment of advanced renal cell carcinoma (RCC) in combination with the tyrosine kinase inhibitor Inlyta...read more